Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Apellis Pharmaceuticals, Inc. incurred term loan of up to $475 million with Sixth Street Lending Partners at 3-month Secured Overnight Financing Rate (SOFR) + 5.75% (subject to 1.00% floor) maturing May 13, 2030.
- Instrument
- term loan
- Principal
- up to $475 million
- Counterparty
- Sixth Street Lending Partners
- Rate
- 3-month Secured Overnight Financing Rate (SOFR) + 5.75% (subject to 1.00% floor)
- Maturity
- May 13, 2030
- Event
- incurrence
Exact text from the filing
Street Lending Partners, as the administrative agent and collateral agent for the Lenders. The Financing Agreement provides for a senior secured term loan facility of up to $475 million (the “Credit Facility”), consisting of an initial draw of $375 million at closing and a potential additional $100 million draw at the Company’s option upon satisfaction of a $50
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Apellis Pharmaceuticals, Inc. entered into Financing Agreement with Sixth Street Lending Partners valued at up to $475 million (effective 2024-05-13).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Sixth Street Lending Partners
- Value
- up to $475 million
- Effective
- 2024-05-13
Exact text from the filing
On May 13, 2024 (the “Closing Date”), Apellis Pharmaceuticals, Inc. (the “Company”) entered into a financing agreement (the “Financing Agreement”) with the guarantors party thereto, the lenders party thereto (the “Lenders”), and Sixth Street Lending Partners, as the administrative agent and collateral agent for the Lenders. The Financing Agreement provides for a senior secured term loan facility of up to $475 million (the “Credit Facility”), consisting of an initial draw of $375 million at closing and a potential additional $100 million draw at the Company’s option upon satisfaction of a $50 million minimum cash requirement and a requirement that the Company’s trailing three-month sales of SYFOVRE were at least $180 million prior to the $100 million draw.
View on SEC.gov